Long-term disease control in multiple myeloma by in-class transitioning: A commu...
Dr Robert Rifkin - Rocky Mountain Cancer Centers, Denver, USA
3 Jul 2020
Venetoclax plus navitoclax in R/R ALL and lymphoblastic lymphoma
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
3 Jul 2020
Treating acute lymphoblastic leukaemia in the era of COVID-19
Dr Elias Jabbour - MD Anderson Cancer Center, Houston, USA
3 Jul 2020
COVID-19 and impact on gynecologic oncology practice in India: Results of a nati...
Dr Anupama Rajanbabu - Amrita Institute of Medical Sciences, Kochi, India
3 Jul 2020
The future of PARP inhibitors in prostate cancer
Dr Elena Castro - Spanish National Cancer Research Center, Madrid, Spain
2 Jul 2020
Managing acute myeloid leukaemia during the COVID-19 pandemic
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
1 Jul 2020
Meet the Expert: Daniel Seymour
Daniel Seymour - BIO Ventures for Global Health, Seattle, USA
1 Jul 2020
Gut microbiome disturbance by antibiotic treatment early in life is sufficient t...
Dr Carolina Vicente-Dueñas - Institute of Biomedical Research of Salamanca, Sala...
30 Jun 2020
COMBI-AD trial: Adjuvant dabrafenib plus trametinib in patients with resected st...
Prof Axel Hauschild - University Hospital, Schleswig-Holstein, Germany
30 Jun 2020
Safety and efficacy of CD19/CD22 CAR T cells in children and young adults with r...
Dr Haneen Shalabi - National Cancer Institute, NIH, Bethesda, USA
30 Jun 2020
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
